Treatment Free Remission – The U.S Perspective

The treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors has been the poster child in the drive to “personalize” cancer therapies by identifying vulnerable molecular targets in different cancers. The results in CML have been somewhat uniquely striking, likely in part because the bcr/abl mutation resulting from the 9;22 translocation is both necessary and sufficient to produce this myeloprolif erative disease in animal models whereas most other cancers have a well characterized “multi-hit” pathogenesis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research